| 摘要 |
<p>The present invention relates to a novel human alternatively spliced Tumor Necrosis-Like Ligand (TRDL) (SEQ ID NO:2). Nucleic acid molecules that encode for the novel TRDL-1γ have been identified and purified. The sequence of such a nucleic acid molecule can be found at SEQ ID NO:1. Provided herein are nucleic acid molecules that encode such TRDL molecules. The present invention also provides recombinant vectors comprising nucleic acid molecules that code for TRDL-1γ. In certain embodiments, these recombinant vectors are plasmids. In certain embodiments, these recombinant vectors are prokaryotic or eukaryotic expression vectors. In certain especially preferred embodiments, the nucleic acid coding for TRDL-1γ is operably linked to a heterologous promoter. The present invention further provides host cells comprising a nucleic acid that codes for TRDL-1γ. TRDL-1 has been shown to stimulate Jurkat cell death. Moreover, TRDL-1 binds to existing members of the TNF receptor family including, FAS and HVEM. Examination of 48 tumor samples revealed high levels of TRDL-1 expression in several tumors including those from the gastrointestinal tract.</p> |
